QUESTION:
Could you explain the pathophysiology of gestational diabetes? Which placental hormones and signals cause insulin resistance? Is insulin not released, or does it fail to work properly? Is there a genetic component? Does the baby develop the same insulin resistance as the mother, or is the baby mainly affected by maternal glucose crossing the placenta?
Quick Answer
Gestational diabetes develops when the normal insulin resistance of pregnancy becomes greater than the mother’s pancreatic beta cells can overcome. Insulin is usually still produced—and often increases—but the rise is insufficient for the degree of resistance. Placental hormones, inflammatory cytokines, free fatty acids and maternal adipose tissue all contribute. Maternal glucose crosses the placenta, but maternal insulin does not meaningfully cross. The fetal pancreas responds by making extra insulin, which can promote excessive growth and neonatal hypoglycemia.
Answer by Dr. Albana Greca, MD, MMedSc
Hello,
Gestational diabetes occurs when maternal beta cells cannot compensate for pregnancy-related insulin resistance. The placenta is central, but beta-cell reserve, body fat, inflammation and genetics also matter.
During the second and third trimesters, insulin sensitivity normally falls so more nutrients remain available to the fetus. Healthy beta cells compensate by increasing insulin secretion.
Gestational diabetes appears when this compensation is inadequate:
Insulin is usually released, often at higher levels, but not enough for the resistance. This resembles type 2 diabetes more than autoimmune type 1 diabetes.
See our guide to how insulin resistance develops.
Important signals include:
Insulin resistance falls rapidly after placental delivery, confirming the placenta’s major role.
No. Human beta-cell adaptation is more complex than simple hyperplasia. Some women enter pregnancy with insulin resistance or limited beta-cell reserve, and pregnancy acts as a metabolic “stress test.”
Gestational diabetes is usually polygenic and overlaps genetically with type 2 diabetes. Variants near MTNR1B, TCF7L2, CDKAL1, GCK, CDKN2A/B and HKDC1 influence glucose or beta-cell function, but each common variant has a modest effect.
HLA-DR3 and HLA-DR4 mainly relate to autoimmune type 1 diabetes, not typical gestational diabetes. Autoimmune diabetes can appear during pregnancy but is uncommon.
Rare monogenic diabetes may also be discovered in pregnancy; genetic testing is reserved for atypical or strongly familial patterns.
Maternal glucose crosses the placenta by facilitated diffusion. Maternal insulin does not meaningfully cross, so the fetus produces its own.
When maternal glucose is high:
The fetus does not simply share the mother’s insulin resistance. The main response is fetal hyperinsulinemia from excess nutrient exposure, with increased later-life metabolic risk.
After the cord is clamped, maternal glucose stops but fetal insulin may remain high, causing neonatal hypoglycemia and the need for newborn monitoring.
Fetal hyperinsulinemia can also contribute to excessive growth, higher oxygen demand, birth injury and delayed lung maturation.
Insulin resistance usually falls rapidly after delivery, so gestational diabetes often resolves. The mother still has increased risk of recurrence and type 2 diabetes.
Postpartum testing is essential. See our gestational diabetes treatment guide.
Gestational diabetes combines pregnancy-induced insulin resistance with insufficient beta-cell compensation. Placental hormones and inflammatory signals impair insulin action; maternal insulin rises but remains inadequate. Glucose crosses the placenta, causing fetal hyperinsulinemia, excessive growth and possible neonatal hypoglycemia. Genetic susceptibility overlaps mainly with type 2 diabetes.
This answer does not replace care.
Click here to post comments or follow up
Ask the Doctor now? Simply click here to return to Controlling Gestational Diabetes.